Slide 1: Fourth Quarter & Year-end 2023 Operating & Financial Results
Fourth Quarter & Year-end 2023 Operating & Financial Results Conference Call / Webinar March 18th, 2024 4:30 PM Eastern Time NASDAQ :LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Contents and Speakers
Contents Speakers Panna Sharma David Margrave 01 Introduction CEO and President CFO 02 2023 and Q4 Highlights 03 Financial Highlights 04 Starlight Therapeutics 05 ADC Program 06 Other Operational Highlights 07 Q&A
Slide 4: 2023 was a transformational year for Lantern Pharma
2023 ü was a transformational year for Lantern Pharma Launched multiple clinical trials for our AI guided drug candidates ü Multiple peer-reviewed publications and posters ü AI platform advancements with RADR® reaching over 60 billion datapoints ü Efficient expansion of clinical infrastructure and ope
Slide 5: 4th Quarter Highlights 1 of 2
2023 ü Multiple clinical trials across three AI-guided drug candidates are active with first expected data and readouts for LP-184 in the second half of 2024. 4th Quarter Next-generation drug development programs Highlights ü approaching IND studies. ü Dosed initial patients in both Phase 1 clinical
Slide 6: 4th Quarter Highlights 2 of 2
Advanced Starlight Therapeutics with hiring of Chief 2023 ü Medical Officer (CMO) and preparing for potential Phase 1B/2 clinical trial in adult CNS tumors beginning in second 4th Quarter half of 2024. Highlights ü Demonstrated significant advancement of our cryptophycin focused antibody-drug-conjug
Slide 7: Lantern's diverse & unique AI-driven pipeline of drug programs
Lantern’s diverse & unique AI-driven pipeline of 11 drug programs including the Phase 2 HarmonicTM trial and RADR® collaborations Lantern Pharma (NASDAQ: LTRN) Orphan Rare Pediatric Lead Candidate Indication Discovery Preclinical Phase I Phase II Designation Disease LP-300 Non-Small Cell Lung Cancer
Slide 8: Summary Results of Operations
Summary Results of Operations Three Months Ended Year Ended December 31, December 31, 2023 2022 2023 2022 Operating expenses: General and administrative $ 1,304,127 $ 1,574,680 $ 5,983,255 $ 5,829,799 Research and development 3,573,257 2,251,598 11,894,315 8,602,954 Total operating expenses 4,877,38
Slide 9: Balance Sheet Highlights & Summary
Balance Sheet Highlights & Summary December 31, 2023 December 31, 2022 Cash and Marketable Securities $41,302,672 $55,196,085 Prepaid Expenses & Other Current Assets $2,038,653 $2,985,472 Total Assets $43,647,616 $58,836,321 Total Liabilities $2,739,682 $2,798,297 Total Stockholders’ Equity $40,907,
Slide 10: Shares Outstanding
Shares Outstanding December 31, 2023 LANTERN PHARMA INC. (LTRN) Common Shares Outstanding* 10,721,192 Warrants 177,998 Options (Employees, Management and Directors) 1,091,196 Fully Diluted Shares Outstanding* 11,990,386 *This includes a share repurchase of 145,348 shares of LTRN common stock at a pu
Slide 11: Starlight has Blockbuster Potential to Provide New Treatment Options
Born from Billions of Datapoints & AI, Starlight has Blockbuster Potential to Provide New Treatment Options for 500,000+ Patients There are over 120 types of central 5 Year Survival nervous system (CNS) and brain Rates of CNS And cancers and a majority have no Brain Cancers effective treatment optio
Slide 12: Multiple Clinical Trials are Planned for STAR-001
Multiple Clinical Trials are Planned for STAR-001 ADULT CNS CANCERS Discovery Preclinical IND Enabling Phase 1A Phase 2 Phase 3 STAR-001 has Multi-billion Market Glioblastoma (GBM) Potential In CNS Cancers Brain Metastases (Breast Cancer) Phase 1A is being conducted by Lantern Pharma $5-6 billion (U
Slide 13: ADC Collaboration Update
Advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC ADC Collaboration Update Key Highlights • The cryptophycin(Cp) drug-payload and Cp-ADC High HER2 Expression Moderate HER2 Expression averaged an 80% cancer cell kill rate • In a mo
Slide 14: Lantern Pharma 2024 Webinar Series
Lantern Pharma 2024 Webinar Series – Webinar Wednesdays – Featuring World-class Collaborators And Researchers Webinars scheduled for coming quarters 1. LP-300 in Never Smokers with Non-Small Cell Lung Cancer with Dr. Joseph Treat of Fox Chase Cancer Center 2. STAR-001 in Brain and CNS cancers with D
Slide 15: Publications Highlighting the Clinical Value of RADR Insights
Publications Highlighting the Clinical Value of RADR® Insights & De-risking the Development of Lantern’s Drug Candidates CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma October 2
Slide 16: RADR's expansion of size, scope, and capabilities
RADR®’s expansion of size, scope, and capabilities continues to push the boundary of AI for oncology drug discovery and development SCALE 100 billion oncology- focused datapoints by end of 2024 SCOPE • Additional classes of compounds including antibodies, checkpoint inhibitors, DNA damaging agents,
Slide 17: Current RADR Modules - Focused on Key Oncology Issues
Current RADR® Modules - Focused on Key Oncology Issues 1 MoA Discovery - Integration of knowledge from biological networks and machine learning to better understand the drugs’ Mechanism of Action 1 MoA Discovery 2 Drug Response Prediction - Machine learning pipelines to Biomarker predict drug respon
Slide 18: 2024 Objectives
2024 Objectives A Breakthrough Year for Lantern ● Advance and expand phase 1 clinical trial for LP-184 T ● Accelerate enrollment in first-in-human clinical trial for LP-284 in NHL + other cancers O ● Expand enrollment of The Harmonic™ Trial to targeted sites in Asia P ● Explore licensing and partner
Slide 19: IR Contact
IR Contact: IR@lanternpharma.com 1-972-277-1136 NASDAQ: LTRN www.lanternpharma.com @LanternPharma CONNECT WITH US